Ultragenyx Pharmaceutical | RARE - Debt

Stock Price
25.00
Daily Change
-0.80 -3.10%
Monthly
1.96%
Yearly
-29.80%
Q2 Forecast
24.50

Ultragenyx Pharmaceutical reported $36M in Debt for its fiscal quarter ending in December of 2025.





Debt Change Date
Acadia Pharmaceuticals USD 52.19M 2.62M Dec/2025
Agios Pharmaceuticals USD 40.21M 4.31M Dec/2025
Alnylam Pharmaceuticals USD 1.28B 30.06M Dec/2025
BioCryst Pharmaceuticals USD 828.6M 510K Dec/2024
BioMarin Pharmaceutical USD 1.44B 833.74M Mar/2026
Esperion Therapeutics USD 262.92M 1.76M Sep/2024
Immunic USD 0 0 Jun/2024
Insmed USD 727.62M 275K Mar/2026
Ionis Pharmaceuticals USD 2.34B 9.5M Mar/2026
Karyopharm Therapeutics USD 299.23M 35.14M Dec/2025
Kyowa Hakko Kirin JPY 28.75B 5.04B Dec/2024
MacroGenics USD 37.01M 238K Sep/2025
Moderna USD 1.31B 571M Dec/2025
Neurocrine Biosciences USD 406.2M 9.1M Mar/2026
PTC Therapeutics USD 286.94M 2.42B Mar/2026
Puma Biotechnology USD 89.06M 55.07M Jun/2024
Regeneron Pharmaceuticals USD 2.71B 300K Mar/2026
Sarepta Therapeutics USD 1.04B 210.44M Dec/2025
Ultragenyx Pharmaceutical USD 36M 2.17M Dec/2025
Vertex Pharmaceuticals USD 1.99B 44M Mar/2026
Xoma USD 120.79M 3.27M Jun/2024